COCP
Cocrystal Pharma, Inc. NASDAQ Listed Feb 22, 2012$1.04
-0.95%
vs $1.05
Mkt Cap $11.7M
52w Low $0.86
16.7% of range
52w High $1.94
50d MA $1.17
200d MA $1.12
P/E (TTM)
-1.4x
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.2x
ROE
-139.5%
P/FCF
-1.4x
RSI (14)
55.40
ATR (14)
$0.05
Beta
1.18
50d MA
$1.17
200d MA
$1.12
Avg Volume
101.0K
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
19805 North Creek Parkway · Bothell, WA 98011 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 | AMC | -0.15 | -0.16 | -6.7% | 1.13 | +0.0% | +1.8% | -1.7% | -0.9% | +0.9% | -0.9% | — |
| May 15, 2026 | AMC | -0.15 | -0.17 | -13.3% | 1.20 | +2.5% | -1.7% | -2.5% | -3.5% | +1.8% | +1.8% | — |
| Mar 31, 2026 | AMC | -0.18 | -0.17 | +5.6% | 1.01 | +4.0% | +1.0% | +48.0% | -0.7% | -2.0% | -2.0% | — |
| Nov 14, 2025 | AMC | -0.22 | -0.19 | +13.6% | 1.03 | +0.0% | -1.0% | +0.0% | -2.9% | -7.1% | -2.0% | — |
| Aug 14, 2025 | AMC | -0.30 | -0.20 | +33.3% | 1.68 | +0.0% | +1.2% | -8.2% | -1.9% | -0.7% | -0.7% | — |
| May 15, 2025 | AMC | -0.52 | -0.23 | +55.8% | 1.44 | +3.5% | -1.4% | -0.7% | +7.8% | -5.9% | +2.1% | — |
| Mar 31, 2025 | AMC | -0.55 | -0.32 | +41.8% | 1.42 | -1.4% | +0.0% | +0.7% | -1.4% | +0.7% | -11.3% | — |
| Nov 13, 2024 | AMC | -0.57 | -0.49 | +14.0% | 1.77 | -1.7% | +24.3% | -2.3% | -3.7% | -0.5% | +0.0% | — |
| Aug 14, 2024 | AMC | -0.51 | -0.53 | -3.9% | 1.70 | +2.4% | +0.6% | +6.4% | +15.4% | -9.0% | +0.0% | — |
| May 13, 2024 | AMC | -0.54 | -0.39 | +27.8% | 1.73 | +1.7% | +8.1% | +12.3% | -6.2% | -1.0% | -2.6% | — |
| Mar 28, 2024 | AMC | -0.57 | -0.44 | +22.8% | 1.40 | +7.1% | +7.1% | -1.3% | -3.4% | +2.8% | +8.8% | — |
| Nov 13, 2023 | AMC | -0.47 | -0.41 | +12.8% | 1.88 | +4.8% | +0.0% | -3.7% | -13.3% | +7.6% | -3.0% | — |
| Aug 14, 2023 | AMC | -0.53 | -0.50 | +5.7% | 3.01 | -0.3% | -2.0% | -3.1% | -4.2% | -0.7% | -2.2% | — |
| May 15, 2023 | AMC | -0.59 | -0.64 | -8.5% | 2.51 | +0.4% | +1.6% | -5.9% | -4.2% | +0.0% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.48 | -4.5% | -3.9% | +5.4% | -1.3% | -1.9% | +2.0% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.96 | $2.12 | +8.2% | +2.0% | +4.0% | +1.4% | -2.4% | -3.4% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.76 | +1.7% | +8.1% | +12.3% | -6.2% | -1.0% | -2.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.43 | $1.43 | +0.0% | +2.8% | +8.8% | -2.5% | -0.6% | +1.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.49 | +4.9% | +7.0% | -0.7% | +1.3% | -2.0% | -0.7% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.79 | +1.7% | +1.7% | +0.0% | +1.7% | +0.5% | -2.2% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.79 | -3.8% | -7.0% | -2.3% | +0.0% | +4.7% | -2.8% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.89 | $1.90 | +0.5% | +3.7% | +4.1% | +0.0% | -4.9% | +2.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.00 | -0.3% | -2.0% | -3.1% | -4.2% | -0.7% | -2.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.95 | +0.0% | -2.0% | +4.2% | -2.0% | -3.1% | -4.2% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.17 | -2.7% | -0.4% | -1.8% | +13.8% | +7.7% | -1.1% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.33 | -2.9% | -5.0% | -2.2% | +1.3% | -1.3% | -3.1% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.39 | +2.1% | +17.9% | +9.4% | -6.6% | -3.9% | -1.1% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.67 | +11.7% | +15.1% | +8.7% | -7.7% | -0.4% | +10.2% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.20 | $10.44 | +2.4% | +3.5% | -1.1% | -2.3% | +0.0% | +1.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Cocrystal Pharma, Inc. -- 8-K 5.02: Executive Change
Jun 9
8-K · 7.01
! Medium
Cocrystal Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 3
8-K · 7.01
! Medium
Cocrystal Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cocrystal Pharma disclosed material information via press release, requiring investors to review Exhibit 99.1 for specific details about company developments or announcements.
May 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cocrystal disclosed material information via Regulation FD, suggesting significant news requiring immediate public disclosure that could materially impact the stock price and investor decisions.
Apr 2
8-K
Unknown — 8-K Filing
Cocrystal's 2025 results and pipeline updates will clarify whether its antiviral candidates are advancing toward commercialization, directly impacting the company's valuation and near-term catalyst timeline.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The 8-K executive change at COCP signals leadership transition; investors should monitor whether the new executive possesses relevant experience to drive shareholder value or if this indicates internal instability.
Mar 13
8-K · 7.01
! Medium
Cocrystal Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cocrystal Pharma disclosed material information via press release, though the specific details require review of the exhibit to assess investor impact on the company's drug development or financial position.
Mar 9
8-K · 7.01
! Medium
Cocrystal Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
I cannot provide a specific analysis as the summary lacks substantive information about the actual disclosure content or business development announced in the press release.
Feb 19
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.
Feb 4
Valuation
Market Cap
$11.7M
Enterprise Value
$4.7M
P/E (TTM)
-1.41x
Forward P/E
—
PEG Ratio
0.02x
P/B
1.85x
P/S
52.18x
P/FCF
-1.43x
EV/EBITDA
—
Shares Out
11.3M
Financials (TTM)
Revenue
$225K
Net Income
-$8.8M
EBITDA
-$8.4M
Free Cash Flow
-$8.2M
Op Cash Flow
-$8.2M
EPS Basic
$-0.78
EPS Diluted
$-0.74
EPS Forward
$-0.67
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$9.7M
Total Liab.
$3.4M
Total Equity
$6.3M
Cash
$7.0M
LT Debt
$0
Book Value/Sh
$0.56
Debt/Equity
0.24x
Current Ratio
3.68
Quick Ratio
3.68
Returns & Growth
ROE
-139.5%
ROA
-90.9%
ROIC
-115.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+54.6%
Price Returns
2W
+7.1%
1M
-1.9%
3M
-30.7%
6M
+4.8%
12M
-31.6%
Technicals
52W High
$1.94
52W Low
$0.86
50d MA
$1.17
200d MA
$1.12
RSI (14)
55.40
ATR (14)
$0.05
Beta
1.18
Avg Volume
101K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 2:26am
· Source: financialmodelingprep.com